Evidence map›Paper›PMID 39390148›Full record

ArticleAAPS PharmSciTech2024

Development of a Versatile High-through-put Oligonucleotide LC-MS Method to Accelerate Drug Discovery.

Changhong Yun, Hyun Chong Woo, Ditte Lovatt, Craig A Parish, Daniel S Spellman, Honglue Shen

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Changhong YunPharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co., Inc., Boston, Massachusetts, 02115, USA.ORCID http://orcid.org/0000-0002-9432-6735
Hyun Chong WooPharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co., Inc., Boston, Massachusetts, 02115, USA.
Ditte LovattBiology-Discovery, Merck & Co., Inc., West Point, Pennsylvania, 19446, USA.
Craig A ParishDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey, 07065, USA.
Daniel S SpellmanPharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co., Inc., West Point, Pennsylvania, 19446, USA.
Honglue ShenPharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co., Inc., Boston, Massachusetts, 02115, USA. honglue.shen@merck.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liquid chromatography-mass spectrometry (LC-MS) is an effective tool for high-throughput quantification of oligonucleotides that is crucial for understanding their biological roles and developing diagnostic tests. This paper presents a high-throughput LC-MS/MS method that may be versatilely applied for a wide range of oligonucleotides, making it a valuable tool for rapid screening and discovery. The method is demonstrated using an in-house synthesized MALAT-1 Antisense oligonucleotide (ASO) as a test case. Biological samples were purified using a reversed liquid-liquid extraction process automated by a liquid handling workstation and analyzed with ion-pairing LC-MS/MS. The assay was evaluated for sensitivity (LLOQ = 2 nM), specificity, precision, accuracy, recovery, matrix effect, and stability in rat cerebrospinal fluid (CSF) and plasma. Besides some existing considerations such as column selection, ion-pairing reagent, and sample purification, our work focused on the following four subtopics: 1) selecting the appropriate Multiple Reaction Monitoring (MRM) transition to maximize sensitivity for trace-level ASO in biological samples; 2) utilizing a generic risk-free internal standard (tenofovir) to avoid crosstalk interference from the oligo internal standard commonly utilized in the LC-MS assay; 3) automating the sample preparation process to increase precision and throughput; and 4) comparing liquid-liquid extraction (LLE) and solid-phase extraction (SPE) as sample purification methods in oligo method development. The study quantified the concentration of MALAT-1 ASO in rat CSF and plasma after intrathecal injection and used the difference between the two matrices to evaluate the injection technique. The results provide a solid foundation for further internal oligonucleotide discovery and development.

Indexed as

Drug DiscoveryTandem Mass SpectrometryAnimalsChromatography, LiquidHigh-Throughput Screening AssaysLiquid Chromatography-Mass SpectrometryLiquid-Liquid ExtractionOligonucleotidesOligonucleotides, AntisenseRatsRNA, Long NoncodingOligonucleotidesOligonucleotides, AntisenseRNA, Long Noncodingcrosstalk-free internal standardhigh-through-putLC–MSoligonucleotide (Oligo)sensitivity improvement

Identifiers

PMID39390148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.